FindTrial
Sign In

rgp120/HIV-1 SF-2

BIOLOGICAL18 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionsHIV SeronegativityPregnancy

Phase 1

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant
CompletedNCT00001019
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Target: 48Updated: 2012-10-30
A Study to Test the Safety of Three Experimental HIV Vaccines
CompletedNCT00000946
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity
End: 2001-03-31Target: 40Updated: 2021-10-29
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
CompletedNCT00001042
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1996-03-31Updated: 2021-11-04
A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
CompletedNCT00000779
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1996-09-30Target: 130Updated: 2021-11-04
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
CompletedNCT00000847
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1999-05-31Target: 150Updated: 2021-11-04
A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection
CompletedNCT00000762
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1996-02-29Target: 72Updated: 2021-11-03
A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers
CompletedNCT00000832
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1998-01-31Updated: 2021-11-04
Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
WithdrawnNCT00001046
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity, Pregnancy
Updated: 2021-11-01
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
CompletedNCT00001072
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1999-01-31Target: 140Updated: 2021-11-04
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules
CompletedNCT00001076
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1997-12-31Target: 34Updated: 2021-11-04
A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
CompletedNCT00000774
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity
End: 1999-01-31Updated: 2021-11-04
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers
CompletedNCT00000813
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1995-06-30Target: 28Updated: 2021-11-04
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
CompletedNCT00001026
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1994-12-31Target: 56Updated: 2021-11-04
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines
CompletedNCT00000746
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1994-07-31Target: 56Updated: 2021-11-04
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months
CompletedNCT00000749
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Target: 14Updated: 2012-10-30
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers
CompletedNCT00001055
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1997-11-30Target: 76Updated: 2021-11-04

Phase 2

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
CompletedNCT00001031
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1997-12-31Updated: 2021-11-04
A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers
CompletedNCT00000871
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 2000-01-31Target: 420Updated: 2021-11-04